Monoclonal antibody drugmaker United BioPharma Inc (聯合生技) yesterday said that its NT$1 billion (US$33.17 million) new plant in Hsinchu County would be able to produce 100kg of antibodies a year and satisfy the need for phase-three clinical trials and early market demand of a new drug.
The new plant will have two production lines, each with a 2,000-liter reactor, company executive director Shugene Lynn (林淑菁) said at an investors’ conference.
“We also reserved the space to build another 10 production lines for the new factory. With the extra lines, United Biopharma will be able to make 600kg of antibodies per year in the future and satisfy the demand of a new drug for the global market,” she added.
Construction is to begin by the end of this year and the factory is expected to be operational in 2016, Lynn said.
The company is developing three monoclonal antibody drug treatments and four monoclonal antibodies for use as biosimilars, company president Liao Mei-june (廖美君) said.
Among these antibodies, UB-421, which is used to treat AIDS, has completed phase-two clinical trials, while the company is to file an investigational new drug application for UB-621, which targets the Herpes simplex virus, by early next year, Liao said.
Other drugs made by the company are still in preclinical trials, she added.
United BioPharma plans to debut on the local Emerging Stock Market (興櫃市場) on Friday, with shares set at NT$85, the company said.
The debut is earlier than the time the company set in November last year.
The company will not release additional shares in its debut, said Victor Sun (孫潤本), the company’s special assistant to the chairperson.
The company’s capital is set at NT$1.15 billion, it said.
United Biomedical Inc Asia (聯亞生技), which manufactures and sells multiple medical products, owns 65 percent of United BioPharma’s shares, while Formosa Plastics Group (台塑集團), the nation’s largest industrial group, owns 25 percent, it added.
In the first half of this year, United Biopharma posted losses of NT$68.41 million, or NT$0.58 per share, because of R&D expenditures of NT$61.48 million, according to the company’s filing with the Taiwan Stock Exchange.
The company does not have comparable data for a year ago, as it was founded on Jan. 16.
Company chairperson Wang Chang-yi (王長怡) said United Biopharma plans to spend less than NT$200 million this year on R&D.
Although it has not yet reported revenue, the company expects to book licensing income next year, Wang said, without offering further information.
When Lika Megreladze was a child, life in her native western Georgian region of Guria revolved around tea. Her mother worked for decades as a scientist at the Soviet Union’s Institute of Tea and Subtropical Crops in the village of Anaseuli, Georgia, perfecting cultivation methods for a Georgian tea industry that supplied the bulk of the vast communist state’s brews. “When I was a child, this was only my mum’s workplace. Only later I realized that it was something big,” she said. Now, the institute lies abandoned. Yellowed papers are strewn around its decaying corridors, and a statue of Soviet founder Vladimir Lenin
ELECTRONICS BOOST: A predicted surge in exports would likely be driven by ICT products, exports of which have soared 84.7 percent from a year earlier, DBS said DBS Bank Ltd (星展銀行) yesterday raised its GDP growth forecast for Taiwan this year to 4 percent from 3 percent, citing robust demand for artificial intelligence (AI)-related exports and accelerated shipment activity, which are expected to offset potential headwinds from US tariffs. “Our GDP growth forecast for 2025 is revised up to 4 percent from 3 percent to reflect front-loaded exports and strong AI demand,” Singapore-based DBS senior economist Ma Tieying (馬鐵英) said in an online briefing. Taiwan’s second-quarter performance beat expectations, with GDP growth likely surpassing 5 percent, driven by a 34.1 percent year-on-year increase in exports, Ma said, citing government
UNIFYING OPPOSITION: Numerous companies have registered complaints over the potential levies, bringing together rival automakers in voicing their reservations US President Donald Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two weeks, ramping up his push to reshape the US’ standing in the global trading system by penalizing purchases from abroad. Administration officials could release details of Trump’s planned 50 percent duty on copper in the days before they are set to take effect on Friday next week, a person familiar with the matter said. That is the same date Trump’s “reciprocal” levies on products from more than 100 nations are slated to begin. Trump on Tuesday said that he is likely to impose tariffs
HELPING HAND: Approving the sale of H20s could give China the edge it needs to capture market share and become the global standard, a US representative said The US President Donald Trump administration’s decision allowing Nvidia Corp to resume shipments of its H20 artificial intelligence (AI) chips to China risks bolstering Beijing’s military capabilities and expanding its capacity to compete with the US, the head of the US House Select Committee on Strategic Competition Between the United States and the Chinese Communist Party said. “The H20, which is a cost-effective and powerful AI inference chip, far surpasses China’s indigenous capability and would therefore provide a substantial increase to China’s AI development,” committee chairman John Moolenaar, a Michigan Republican, said on Friday in a letter to US Secretary of
RSS